DailyIQ
Last updated1 minute ago

GKOS·Glaukos Corporation

$166.27
+0.77 (+0.47%)
High
$167.37
Open
$164.94
Market Cap
9.99B
52W High
$191.62
Low
$164.89
P. Close
$166.27
P/E
-
52W Low
$73.16
Fwd P/E
315.64
DailyIQ Est.
$204.12
Inst. Ownership
59.3%
Short Interest
6.38%
Days to Cover
4.1
Technical Score (1D)
59
BULLISH
News Sentiment
60
BULLISH
On Oct 11, Glaukos Corporation announced its iDose TR platform, a technology that enables sustained drug delivery and expands the company’s reach beyond surgical implants into glaucoma and retinal therapies. The company highlighted potential new revenue streams from this technology, noting that reimbursement policies and patient access would influence commercial success. Analysts cautioned that Glaukos’s high valuation makes the stock vulnerable to operational setbacks, leading to a neutral stance on the shares. The announcement underscored the company’s intent to diversify its product portfolio while acknowledging the regulatory and reimbursement challenges that could impact the commercial viability of the new therapies.
LOW TARGET
$172 +3.5%
2 analysts
MEAN TARGET
$199 +19.5%
7 analysts
HIGH TARGET
$225 +35.3%
13 analysts
PRICE RANGE
$172.00 - $225.00
SB / B / H / S / SS
8/10/2/1/1
DAILYIQ EST.
$204.12 (+22.8%)
Bought (1Y)
0 shares
$0
Sold (1Y)
139,219 shares
$23.9M
Navratil TomasCHIEF DEVELOPMENT OFFICER
Sell312 shares2026-10-05
Navratil TomasCHIEF DEVELOPMENT OFFICER
Sell327 shares2026-10-05
Navratil TomasCHIEF DEVELOPMENT OFFICER
Sell888 shares2026-10-05
Navratil TomasCHIEF DEVELOPMENT OFFICER
Sell1,083 shares2026-09-25
Navratil TomasCHIEF DEVELOPMENT OFFICER
Sell229 shares2026-09-25
48/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✕Negative net margin
✕Negative operating cash flow
Gross Margin
55.7%
Net Margin
-37.0%
Revenue CAGR
30.4%
Current Ratio
4.69x
Debt / Equity
0.01x
Return on Equity
-28.6%

EPS

EstBeatMiss
$-0.29$-0.23$-0.18$-0.12$-0.06Q3'25Q3'26
QtrEstActual+/−
Q3'26$-0.09 - -
Q3'25$-0.26$-0.16+38.9%

Revenue

EstBeatMiss
$128M$140M$152M$165M$177MQ3'25Q3'26
QtrEstActual+/−
Q3'26$171M - -
Q3'25 - $134M -

Market Data

GKOS Stock Snapshot

NEUTRAL59/100
$166.27+$0.77 (0.5%)
Market cap
9.99B
Day range
$164.89 – $167.37
News sentiment
60/100 · Bullish
Analyst target
$198.69 (+19.5%)
Consensus
Buy · 22 analysts
52-week range+127.3% off low · -13.2% from high
$73.16$191.62
Price $166.27 DailyIQ Est. $204.12

The technical read on GKOS is balanced, which usually means the market is waiting on a catalyst. Thinner liquidity means moves can extend past what the fundamentals alone justify.

Behaviour On Record

What GKOS's own history says about today's numbers

Realized volatility (21d)
47.4% 59th pct
Below its peak
-12.6%
vs 200-day average
+21.1%
Up days (1y)
49%

Glaukos Corporation is currently running 47.4% annualised volatility over the last 21 sessions. Measured against GKOS's own 11 years of daily returns rather than a market-wide average, that is the 59th percentile — close to its own typical level, against a typical reading of 43.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

GKOS is trading -12.6% below its running peak. Across 10 full years on file, its median worst-drawdown-in-a-year was -43.2%, and the deepest was -63.6% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +21.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 63rd percentile — a somewhat wider gap than its own norm. Over the past year GKOS closed higher on 49% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 11 years of records, GKOS finished the month higher 6 of 11 times, with a median return of +2.9% and an average of -0.3%. Its strongest month historically has been June at +12.3% on average, its weakest March at -4.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: GKOS has opened more than 2% away from the prior close in 242 of 2,841 sessions (8.5% of the time), with the largest gaps running +20.6% and -21.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 2,842 daily closes between 2015-06-25 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against GKOS's own 11-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of GKOS's sector?

Glaukos Corporation sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for GKOS?

CallsPuts

For Glaukos Corporation's nearest expiry (2026-10-16, 2 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 1.44), with at-the-money implied volatility around 61.2%. The options market is pricing roughly a ±4.7% move by that expiry — a range of about $158.62–$174.12.

Put/call ratio (2026-10-16)
1.44
ATM implied volatility
61.2%
Total open interest
7,620
Expected move by 2026-10-16
±4.7% ($158.62–$174.12)

Analyst Rating Changes

Are analysts turning bullish or bearish on GKOS?

BTIG most recently reiterated its rating on Glaukos Corporation to Buy on Oct 12, 2026 with a price target of $205 (from $202). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
BTIG — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 12, 2026BTIGMaintainedBuy$202 → $205
Sep 22, 2026JefferiesMaintainedBuy$190 → $210
Aug 20, 2026BTIGMaintainedBuy$193 → $202
Jul 30, 2026UBSMaintainedNeutral$150 → $172
Jul 30, 2026HC Wainwright & Co.MaintainedBuy$168 → $195
Jul 30, 2026CitigroupMaintainedBuy$175 → $188
Jul 30, 2026Piper SandlerReiteratedOverweight$165 → $195
Jul 30, 2026JefferiesMaintainedBuy$165 → $190
Jul 30, 2026StifelMaintainedBuy$175 → $190
Jul 30, 2026Truist SecuritiesMaintainedBuy$180 → $215
Jul 30, 2026Wells FargoMaintainedOverweight$138 → $178
Jul 30, 2026NeedhamMaintainedBuy$150 → $201

ETF holders

ETFs holding GKOS

News Sentiment Analysis

Sentiment gathered from recent headlines

60/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
BTIG analyst Ryan Zimmerman upgraded Glaukos (GKOS) to a Buy rating and raised the price target from $202 to $205. The upgrade reflects confidence in the company’s pipeline and recent clinical progress. The new target suggests a modest upside potential for investors. The rating change is expected to support GKOS’s market perception and may influence short‑term trading activity.
What did this article say?
Glaukos Corporation (GKOS) announced its iDose TR platform, enabling sustained drug delivery and extending its reach beyond surgical implants into glaucoma and retinal therapies. The company highlighted potential new revenue streams from this technology, while noting that reimbursement policies and patient access will influence commercial success. Despite these growth prospects, analysts cautioned that GKOS’s high valuation makes the stock vulnerable to setbacks, leading to a neutral stance on the shares.
What did this article say?
Glaukos reported Q2 net sales that grew 50% year‑over‑year to $185.6 million, largely driven by the iDose TR and the launch of Epioxa. The company achieved a non‑GAAP gross margin of 85% and reached breakeven on its profit‑and‑loss statement. Management subsequently raised its 2026 net sales guidance to between $680 and $700 million, projecting iDose TR sales of $275–$280 million and a corneal health growth rate above 20%. Medicare coverage limitations present a real but non‑binary risk to iDose TR growth, while Epioxa provides a second growth engine.
What did this article say?
Glaukos Corporation announced a licensing agreement with RevOpsis Therapeutics to develop and commercialize RO‑104, a tri‑specific biologic for retinal diseases. The deal grants GKOS exclusive rights to RevOpsis’ RevMod platform, enabling the company to pursue up to four additional retinal biologic candidates. Management highlighted RO‑104’s potential to inhibit three angiogenic pathways simultaneously, positioning it as a first‑in‑class therapy that could strengthen GKOS’s retinal franchise and support long‑term innovation.
What did this article say?
Glaukos reported Phase 4 data for its iDose TR therapy, showing it reduced intraocular pressure more effectively than cataract surgery alone. The study confirmed the therapy’s superior efficacy in a large patient cohort, strengthening the company’s clinical portfolio. These results support the company’s ongoing development plan and may enhance future regulatory submissions.
What did this article say?
Glaukos reported that the phase 4 clinical trial of iDose TR met its primary efficacy endpoint. The study showed statistically significant superiority in reducing mean diurnal intraocular pressure when combined with cataract surgery compared to surgery alone. Safety data through three months were favorable, with no treated‑related adverse events of corneal endothelial cell loss or cystoid macular edema, and no serious corneal adverse events. The results support the continued development of iDose TR for patients with open‑angle glaucoma or ocular hypertension.
What did this article say?
Glaukos Corporation announced that its Phase 4 randomized controlled trial of iDose® TR combined with cataract surgery met its primary efficacy endpoint, achieving a statistically significant and clinically meaningful reduction in intraocular pressure (IOP) of 11.1 mmHg compared to surgery alone. The study enrolled patients with open-angle glaucoma and demonstrated a favorable safety profile through three months of follow‑up. These topline results support the therapeutic potential of iDose® TR as an adjunct to cataract surgery and may strengthen Glaukos’ position in the glaucoma treatment market.
What did this article say?
Glaukos Corporation announced that its Phase 4 trial of iDose TR combined with cataract surgery met the primary efficacy endpoint, showing statistically significant and clinically meaningful intra‑ocular pressure reduction compared with cataract surgery alone. The study enrolled patients with open‑angle glaucoma or ocular hypertension and demonstrated superiority in IOP control. The positive topline results support the company’s strategy to expand iDose TR’s indication and strengthen its product pipeline.
What did this article say?
Glaukos Corporation released positive topline data from its GLK‑202‑03 Phase 3 extension study of Epioxa, showing durable efficacy and safety over three years in keratoconus patients. The company simultaneously announced an exclusive licensing agreement to expand its retinal disease pipeline. The combined results strengthen GKOS’s corneal portfolio and broaden future revenue opportunities.
What did this article say?
Glaukos reported positive three‑year topline results from a Phase 3 extension study of its Epioxa corneal cross‑linking therapy, showing durable efficacy, clinically meaningful visual gains, and no serious safety events in keratoconus patients. The data highlight Epioxa’s incision‑free, long‑term benefit profile and suggest it could reshape routine keratoconus treatment. The findings reinforce Glaukos’ corneal portfolio narrative and support continued focus on its iDose TR platform.

Technical Analysis

Real-time indicators across multiple timeframes

59
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $4.56B combined position · 14 adding, 11 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy9,540,05615.80%$1.33B2026-08-07
Vanguard Group Inc▼ Sell6,020,4929.97%$679.77M2026-01-29
Janus Henderson Group plc▲ Buy5,348,3958.86%$575.84M2026-05-18
Millennium Management LLC▲ Buy1,581,0162.62%$220.96M2026-08-14
Geode Capital Management, LLC▲ Buy1,463,4482.42%$204.57M2026-08-12
Citadel Advisors LLC▼ Sell1,390,0172.30%$194.27M2026-09-02
Capital World Investors▲ Buy1,015,9431.68%$141.99M2026-08-12
AllianceBernstein L.P.▼ Sell1,254,7032.08%$135.08M2026-08-14
Goldman Sachs Group Inc▼ Sell897,0211.49%$125.37M2026-08-14
Invesco Ltd.▼ Sell706,8771.17%$98.79M2026-08-14
William Blair Investment Management, LLC▼ Sell661,6751.10%$92.48M2026-08-12
Northern Trust Corp▲ Buy612,4961.01%$85.60M2026-08-13
Morgan Stanley▼ Sell589,7930.98%$82.43M2026-08-13
Bank of America Corp▼ Sell587,3270.97%$82.08M2026-08-14
Norges Bank▼ Sell498,5020.83%$69.67M2026-08-12
Balyasny Asset Management L.P.▲ Buy491,6360.81%$68.71M2026-08-14
Loomis Sayles & Co L P▲ Buy469,3880.78%$65.60M2026-08-14
Wellington Management Group LLP▲ Buy428,2150.71%$59.85M2026-08-14
FMR LLC (Fidelity)▲ Buy377,4850.63%$52.76M2026-08-13
Marshall Wace, LLP▲ Buy314,8040.52%$44.00M2026-08-13
Artisan Partners Limited Partnership▼ Sell309,2660.51%$43.22M2026-08-13
Neuberger Berman Group LLC▲ Buy300,7520.50%$42.03M2026-08-13
JPMorgan Chase & Co▼ Sell172,1860.29%$24.86M2026-08-12
Renaissance Technologies LLC▲ Buy147,1920.24%$20.57M2026-08-13
Prudential Financial Inc▲ Buy139,5270.23%$19.50M2026-08-12
Q2 2026 flow:2.38M sh bought ($332.11M)1.94M sh sold ($267.77M)net +432.5K sh (+$64.33M)